In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

Access to medicines is “one of the most challenging policy areas in every country in the European region ... is leading to additional health benefits and health gains, but they are ...

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

"The bottom line is that withdrawing from the WHO makes Americans and the world less safe," says Dr. Tom Frieden, president and CEO of the nonprofit health organization Resolve to Save Lives and ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

Here, Seema Jaitly cuts through the confusion to provide a step-by-step guide to writing a Periodic Benefit Risk Evaluation ... but the European Medicines Agency (EMA) is starting to publish ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

The FDA agreed with the pre-surgical selection of patients most likely to benefit from Multikine ... letters were received from the European Medicines Agency (EMA) Paediatric Committee and ...

The US president's tariffs are already causing turmoil on the ASX as investors prepare for a global trade war, and the Greens ...

The General Pharmaceutical Council (GPhC), which regulates pharmacies, said it was responding to concerns relating to the unsafe prescribing and supply of medicines ... said the regulatory agency.

As the WHO reviews coca leaves' international scheduling status, momentum is growing to address this injustice to Indigenous Andean peoples.